Under Evaluation
English Title: Advanced Medicine
ISSN (Print): 3105-6725
ISSN (Online): 3105-6733
CODEN: XYABBJ (International Standard Serial Number, a globally unique identifier assigned by the Chemical Abstracts Service (CAS), USA)
Publication Model: Gold Open Access (Gold OA), licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0), with permanent free full-text access
Publisher: Macau Sino-Foreign Medical Publishing Limited
Publication Frequency: Bimonthly
Languages of Publication: Chinese, English
Submission Language: Chinese (English title, abstract, keywords, author affiliations and names are required)
Distribution Support: China International Book Trading Corporation (CIBTC)
Import Registration Number: G015Z124
The journal has been indexed by many authoritative academic databases worldwide. It is committed to promoting the global dissemination of high-quality research and collaborating with scholars around the world to build an open, collaborative and forward-looking international academic community.
Advanced Medicine is an international academic journal focusing on medical innovation and clinical translation. The journal is dedicated to building an efficient and solid bridge between basic medical research, innovative drug research and development, and clinical diagnosis and treatment practice, promoting the rapid translation of cutting-edge scientific discoveries into addressing practical clinical needs. We pay close attention to the latest breakthroughs in precision medicine, new therapies (including cell therapy, gene therapy, etc.) and translational medicine. We particularly encourage the integration of multidisciplinary wisdom and the adoption of interdisciplinary research paradigms to provide a solid academic engine and knowledge foundation for promoting the development of the global medical innovation system.
The journal regularly solicits original, high-quality research papers, reviews and methodological discussions in the following fields:
Precision medicine and personalized drug therapy
Innovative drug design and development (small-molecule drugs, large-molecule biopharmaceuticals, etc.)
Cell and gene therapy technologies
Biologics and new vaccine research and development
Preclinical research and translational medicine
Innovative clinical diagnosis and treatment protocols (including clinical trial design, real-world research)
Drug delivery systems and formulation technologies
Medical artificial intelligence and digital medicine
New therapies for rare diseases and major diseases
Pharmacoeconomics and medical policy research
Manuscript Nature: Submissions must be original, unpublished academic achievements with clear scientific innovation or clinical translation potential.
Language Requirement: The main text of the manuscript must be written in Chinese.
Required Information: When submitting, please provide the following Chinese-English bilingual information completely:
Article title (Chinese and English)
Author information: Names of all authors, affiliated institutions (Chinese and English), and profiles of the first author/corresponding author (including research direction and email address)
Abstract: Chinese and English structured abstracts, which should clearly elaborate on the research purpose, methods, core findings and main conclusions
Keywords: 3-5 Chinese and English keywords
Peer Review: The journal implements a strict international double-blind peer review system to ensure the academic quality and rigor of published results.
The journal's vision is to become an important journal with both academic authority and practical influence in the field of medical innovation in China and even the world. We are committed to building an open, rigorous and dynamic academic community. By promoting the dissemination and exchange of high-level research results, we effectively link laboratory research, clinical development and industrial application, contributing knowledge and wisdom to addressing global major health challenges and promoting the progress of human health.
| VOLUME | ISSUE | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|